Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 11;13(1):194-203.
doi: 10.18632/aging.202495. Epub 2021 Jan 11.

Prognostic potential of cardiac structural and functional parameters and N-terminal propeptide of type III procollagen in predicting cardiac fibrosis one year after myocardial infarction with preserved left ventricular ejection fraction

Anastasia Osokina  1 , Viktoria Karetnikova  1 , Olga Polikutina  1 , Anna Ivanova  1 , Olga Gruzdeva  1 , Yulia Dyleva  1 , Aleksandr Kokov  1 , Natalia Brel  1 , Tamara Pecherina  1 , Olga Barbarash  1
Affiliations

Prognostic potential of cardiac structural and functional parameters and N-terminal propeptide of type III procollagen in predicting cardiac fibrosis one year after myocardial infarction with preserved left ventricular ejection fraction

Anastasia Osokina et al. Aging (Albany NY). .

Abstract

The aim of the study were to evaluate the prognostic potential of serum level of N-terminal propeptide procollagen type III (PIIINP) and heart parameters for predicting heart cardiac fibrosis 1 year after ST-segment elevation myocardial infarction (STEMI) with preserved left ventricular ejection fraction (LVEF). 68 patients with STEMI and preserved LVEF with acute heart failure of the I-III degree according to the Killip classification were examined. Echocardiography was performed and PIIINP levels were measured on days 1 and 12, as well as 1 year after STEMI. A year after STEMI, was performed contrast magnetic resonance imaging and patients were assigned into four groups depending on the severity of cardiac fibrosis: cardiac fibrosis 0% (n=49, 57% of 86 patients); ≤5% (n=18, 20.9%); 6-15% (n=10, 11.6%); ≥16% (n=9, 10.5%). Direct correlations between the severity of cardiac fibrosis, PIIINP level and indicators of diastolic function were established. The risk of cardiac fibrosis increases at the level of PIIINP ≥381.4 ng / ml on the 12th day after STEMI with preserved LVEF (p=0.048). Thus, measuring the level of PIIINP in the inpatient period can allow timely identification of patients with a high risk of cardiac fibrosis 1 year after STEMI with preserved LVEF.

Keywords: cardiofibrosis; diastolic dysfunction; heart failure; myocardial infarction.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Progress in PIIINP levels within 1 year after STEMI. PIIINP, N-terminal propeptide of Type III procollagen; STEMI, ST-segment elevation myocardial infarction.
Figure 2
Figure 2
Progress in systolic function depending on cardiac fibrosis according to the MRI findings within the 1-year follow-up. MRI, magnetic resonance imaging; LVEF, left ventricular ejection fraction.
Figure 3
Figure 3
1-year progress in PIIINP levels in relation to the severity of cardiac fibrosis evaluated by MRI. PIIINP, N-terminal propeptide of Type III procollagen; MRI, magnetic resonance imaging.
Figure 4
Figure 4
The results of the correlation analysis depending on the prevalence of cardiac fibrosis measured with MRI one year after STEMI with preserved LVEF. MRI, magnetic resonance imaging; LVEF, left ventricular ejection fraction; STEMI, ST-segment elevation myocardial infarction; MI, myocardial infarction; mPAP, mean pulmonary artery pressure.
Figure 5
Figure 5
The cut-off value of PIIINP level at day 12 post-MI with preserved LVEF within 1-year follow-up (ROC curve).
See this image and copyright information in PMC

References

    1. Ambale-Venkatesh B, Liu CY, Liu YC, Donekal S, Ohyama Y, Sharma RK, Wu CO, Post WS, Hundley GW, Bluemke DA, Lima JA. Association of myocardial fibrosis and cardiovascular events: the multi-ethnic study of atherosclerosis. Eur Heart J Cardiovasc Imaging. 2019; 20:168–76. 10.1093/ehjci/jey140 - DOI - PMC - PubMed
    1. Ferreira JP, Kraus S, Mitchell S, Perel P, Piñeiro D, Chioncel O, Colque R, de Boer RA, Gomez-Mesa JE, Grancelli H, Lam CS, Martinez-Rubio A, McMurray JJ, et al.. World heart federation roadmap for heart failure. Glob Heart. 2019; 14:197–214. 10.1016/j.gheart.2019.07.004 - DOI - PubMed
    1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, et al., and American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018; 137:e67–492. 10.1161/CIR.0000000000000558 - DOI - PubMed
    1. Bloom MW, Greenberg B, Jaarsma T, Januzzi JL, Lam CS, Maggioni AP, Trochu JN, Butler J. Heart failure with reduced ejection fraction. Nat Rev Dis Primers. 2017; 3:17058. 10.1038/nrdp.2017.58 - DOI - PubMed
    1. Gandhi PU, Gaggin HK, Redfield MM, Chen HH, Stevens SR, Anstrom KJ, Semigran MJ, Liu P, Januzzi JL Jr. Insulin-like growth factor-binding protein-7 as a biomarker of diastolic dysfunction and functional capacity in heart failure with preserved ejection fraction: results from the RELAX trial. JACC Heart Fail. 2016; 4:860–69. 10.1016/j.jchf.2016.08.002 - DOI - PMC - PubMed

Publication types